Compare Crispr Therapeutics AG (CRSP) vs Dell Technologies Inc (DELL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Dell Technologies Inc — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while Dell Technologies Inc trades at $455 (market cap $284.93B). The key difference: Dell Technologies Inc is far larger — about 54.5× Crispr Therapeutics AG's market cap, and Dell Technologies Inc pays a 0.57% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | DELL | |
|---|---|---|
Market Cap | $5.23B | $284.93B |
Sector | Health | Technology |
52-Week High | $76.78 | $467.27 |
52-Week Low | $44.34 | $111.10 |
Enterprise Value | $3.65B | $304.51B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Dell Technologies stock trades at $457.93, up 0.92% on the day, near its 52-week high. Recent earnings beats, including Q1 2026 EPS of $4.86 versus $2.96 expected, highlight strong operational performance. The technical outlook is bullish with support at $448 and resistance at $471. Revenue for 2025 reached $95.57 billion with net income of $4.59 billion, though cash flow trends show net outflows.
The outlook remains positive driven by AI server demand and commercial PC refresh cycles, with a consensus price target of $503.76 implying 10% upside. Risks include valuation concerns at a P/E of 35.14 and competitive pressures in the tech hardware sector. Institutional sentiment is bullish with 57.78% of analysts rating Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →
